Trabectedin and the L-Sarcomas: A Decade-Long odyssey

Journal of Clinical Oncology

Volumn 34, Issue 8, 2016, Pages 769-771

  Schwartz, Gary K ^a  

^a Columbia University School of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; PAZOPANIB; TRABECTEDIN; ALKYLATING AGENT;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DNA DAMAGE; EDITORIAL; HUMAN; HYPERTRANSAMINASEMIA; LEIOMYOSARCOMA; LIPOSARCOMA; MYXOSARCOMA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DNA INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOFT TISSUE SARCOMA; THERAPY DELAY; SARCOMA;

ANTINEOPLASTIC AGENTS, ALKYLATING; HUMANS; SARCOMA;

EID: 84961160296     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.5938     Document Type: Editorial

References (17)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
2. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2, 185 patients treated with anthracycline-containing first-line regimens-A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 17:150-157, 1999.
3. Demetri GD, von Mehren M, Jones RL, et al: Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial. J Clin Oncol 34:786-793, 2016.
4. Zewail-Foote M, Hurley L: Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove. J Med Chem 42:1493-1497, 1999.
5. Demetri GD, Chawla SP, von Mehren M, et al: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules. J Clin Oncol 27:4188-4196, 2009.
6. Garcia-Carbonero R, Supko JG, Manola J, et al: Phase II and pharmacokinetic study of Ecteinascidin-743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22:1480-1490, 2004.
7. Le Cesne A, Blay JY, Judson I, et al: Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 23:576-584, 2005.
8. Yovine A, Riofrio M, Blay JY, et al: Phase II study of Ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22:890-899, 2004.
9. Abbas Manji G, Singer S, Koff A, et al: Application of molecular biology to individualize therapy for patients with liposarcoma. Am Soc Clin Oncol Ed Book 35:213-218, 2015.
10. Blay JY, Leahy MG, Nguyen BB, et al: Randomized phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer 50:1137-1147, 2014.
11. Barretina J, Taylor BS, Banerji S, et al: Subtype-specific genomic alterations define new targets for soft-Tissue sarcoma therapy. Nat Genet 42:715-721, 2010.
12. Singer S, Socci ND, Ambrosini G, et al: Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 67:6626-6636, 2007.
13. Dickson MA, Tap WD, Keohan ML, et al: Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-Amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 31:2024-2028, 2013.
14. van der Graaf WT, Blay JY, Chawla SP, et al: Pazopanib for metastatic softtissue sarcoma (PALETTE): A randomized, double-blind, placebo-controlled phase III trial. Lancet 379:1879-1886, 2012.
15. Sleijfer S, Ray-Coquard I, Papai Z, et al: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European Organisation for Research andTreatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol 27:3126-3132, 2009.
16. Schö ffski P, Maki R, Italiano A, et al: Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). J Clin Oncol 33:560s, 2015 (suppl;abstr LBA10502).
17. Cortes J, O'Shaughnessy J, Loesch D, et al: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase III open-label randomized study. Lancet 377:914-923, 2011.